Literature DB >> 24070075

Intracranial stenting for severe symptomatic stenosis: self-expandable versus balloon-expandable stents.

Soonchan Park1, Jae-Hyuk Kim, Jae Kyun Kwak, Hye Jin Baek, Bo Hyun Kim, Dong-Geun Lee, Deok Hee Lee, Jong Sung Kim, Dae Chul Suh.   

Abstract

Intracranial atherosclerosis against optimal medical treatment requires reperfusion therapy to improve the clinical outcome. We compared outcomes between self-expandable stent (SES) and/or balloon-expandable stent (BES) and present the potential advantages of using each stent. During the same time frame before and after Wingspan introduction to our institute, 115 consecutive patients underwent intracranial stenting for symptomatic severe intracranial stenosis against optimal medical treatment using BES alone (n = 71) vs. BES or SES (n = 44). We analyzed 15 factors including outcome related to an adverse event (AE), modified Rankin Scale (mRS) and restenosis at six months and retrospectively compared the potential advantages of using each stent. BES or SES groups had a significantly lower AE rate (2.3%) than the BES only group (14%) (P = 0.049) revealing mRS of ≤ 2 in all patients at six months compared to 93% of the patients in the BES group. Analysis of BES or SES subgroups revealed that BES was associated with less residual stenosis after stenting than SES (18 vs. 32%; P < 0.001). Both SES and BES can improve the clinical outcome of intracranial stenting especially with a selective choice of SES or BES. Further study is needed to analyse the difference in long-term outcome and the restenosis rate between SES and BES.

Entities:  

Mesh:

Year:  2013        PMID: 24070075      PMCID: PMC3806001          DOI: 10.1177/159101991301900303

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  21 in total

1.  Perforator stroke after elective stenting of symptomatic intracranial stenosis.

Authors:  Thomas W Leung; Henry Mak; Simon C H Yu; Ka-Sing Wong
Journal:  Neurology       Date:  2007-04-10       Impact factor: 9.910

2.  The therapeutic time window related to the presenting symptom pattern, that is, stable versus unstable patients, can affect the adverse event rate of intracranial stenting.

Authors:  Dae Chul Suh; Eun Hye Kim
Journal:  Stroke       Date:  2009-09-10       Impact factor: 7.914

3.  Intracranial stenting of subacute symptomatic atherosclerotic occlusion versus stenosis.

Authors:  Peng-Hua Lü; Jee Won Park; Soonchan Park; Jong Lim Kim; Deok Hee Lee; Sun Uck Kwon; Jong Sung Kim; Sung-Cheol Yun; Dae Chul Suh
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

4.  Perforator stroke after elective stenting of symptomatic intracranial stenosis.

Authors:  W J Jiang; T Srivastava; F Gao; B Du; K H Dong; X T Xu
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

5.  High shear stress at the surface of enhancing plaque in the systolic phase is related to the symptom presentation of severe M1 stenosis.

Authors:  Dae Chul Suh; Sung-Tae Park; Tack Sun Oh; Sang-Ok Park; Ok Kyun Lim; Soonchan Park; Chang Woo Ryu; Deok Hee Lee; Young Bae Ko; Sang-Wook Lee; Kyunghwan Yoon; Jong Sung Kim
Journal:  Korean J Radiol       Date:  2011-07-22       Impact factor: 3.500

6.  Stenting versus aggressive medical therapy for intracranial arterial stenosis.

Authors:  Marc I Chimowitz; Michael J Lynn; Colin P Derdeyn; Tanya N Turan; David Fiorella; Bethany F Lane; L Scott Janis; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; Michel T Torbey; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft
Journal:  N Engl J Med       Date:  2011-09-07       Impact factor: 91.245

7.  Adjuvant revascularization of intracranial artery occlusion with angioplasty and/or stenting.

Authors:  Jin Woo Choi; Jae Kyun Kim; Byung Se Choi; Jeoung Hyun Kim; Hae Jun Hwang; Jong Sung Kim; Sang Joon Kim; Dae Chul Suh
Journal:  Neuroradiology       Date:  2008-09-26       Impact factor: 2.804

8.  Prognostic factors for neurologic outcome after endovascular revascularization of acute symptomatic occlusion of the internal carotid artery.

Authors:  D C Suh; J K Kim; C G Choi; S J Kim; H W Pyun; C Ahn; D H Yang; K S Lim; J-G Leem; K D Hahm; J-H Lee; S U Kwon; J S Kim
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

9.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

10.  Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.

Authors:  R L Sacco; D E Kargman; Q Gu; M C Zamanillo
Journal:  Stroke       Date:  1995-01       Impact factor: 7.914

View more
  8 in total

1.  Percutaneous transluminal angioplasty and stenting for severe stenosis of the intracranial extradural internal carotid artery causing transient ischemic attack or minor stroke.

Authors:  Jun Kyeung Ko; Chang Hwa Choi; Seung Heon Cha; Byung Kwan Choi; Won Ho Cho; Tae Ho Kang; Sang Min Sung; Han Jin Cho; Tae Hong Lee
Journal:  Interv Neuroradiol       Date:  2015-06-10       Impact factor: 1.610

2.  Outcomes of middle cerebral artery angioplasty and stenting with Wingspan at a high-volume center.

Authors:  Zi-Liang Wang; Bu-Lang Gao; Tian-Xiao Li; Dong-Yang Cai; Liang-Fu Zhu; Jiang-Yu Xue; Wei-Xing Bai; Zhao-Shuo Li
Journal:  Neuroradiology       Date:  2015-10-29       Impact factor: 2.804

3.  Medium-term results of undersized angioplasty and stenting for symptomatic high-grade intracranial atherosclerotic stenosis with Enterprise.

Authors:  Aysun Erbahceci Salik; Hatem H Selcuk; Hasanagha Zalov; Fatih Kilinc; Musa Cirak; Batuhan Kara
Journal:  Interv Neuroradiol       Date:  2019-04-16       Impact factor: 1.610

4.  The effectiveness of enterprise stent use on the treatment of intracranial atherosclerosis disease.

Authors:  Oguz Ari; Omer F Nas; Mehmet F Inecikli; Bahattin Hakyemez
Journal:  Neuroradiol J       Date:  2022-04-07

5.  Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis.

Authors:  G Peng; Y Zhang; Z Miao
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-30       Impact factor: 3.825

6.  Endovascular Treatment of Intracranial Atherosclerotic Stenosis: Current Debates and Future Prospects.

Authors:  Jichang Luo; Tao Wang; Peng Gao; Timo Krings; Liqun Jiao
Journal:  Front Neurol       Date:  2018-08-21       Impact factor: 4.003

7.  Endovascular treatment for symptomatic intracranial artery stenosis: protocol for a systematic review and network meta-analysis.

Authors:  Tao Wang; Xue Wang; Kun Yang; Jing Zhang; Jichang Luo; Peng Gao; Yan Ma; Liqun Jiao; Feng Ling
Journal:  BMJ Open       Date:  2018-07-10       Impact factor: 2.692

8.  Edaravone reduces depression severity in patients with symptomatic intracranial stenosis and is associated with the serum expression of sex hormones.

Authors:  Zhaohong Kong; Jian Jiang; Ming Deng; Zhaohui Zhang; Gaohua Wang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.